Use of 2,4,5-trisubstituted 1,2,4-triazolones in antiviral therapy
By developing the 2,4,5-trisubstituted 1,2,4-triazolone compound BAY2402234, the lack of effective antiviral drugs in the prior art was solved, and the broad-spectrum inhibition and low cytotoxicity of a variety of viruses were achieved, especially the effective inhibition of SARS-CoV-2.
Patent Information
- Application Number
- JP2023503228
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-07-17
- Filing Date
- 2021-07-15
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-07-15
AI Technical Summary
The prior art lacks effective antiviral drugs, especially specific drugs for the novel coronavirus SARS-CoV-2, and common viral infections such as influenza, dengue, and Bunia virus lack broad-spectrum inhibitors.
Using the 2,4,5-trisubstituted 1,2,4-triazolone compound BAY2402234, an antiviral drug with low cytotoxicity was developed to prevent and treat multiple viral infections by inhibiting viral replication and inducing cell differentiation.
BAY2402234 shows significant antiviral activity against a variety of viruses, especially SARS-CoV-2, which can effectively inhibit viral replication, reduce cytotoxicity, and provide broad-spectrum prevention and treatment effects.
Smart Images

Figure 0007594084000008 
Figure 0007594084000009 
Figure 0007594084000001
Abstract
Description
[Technical field]
[0001] This application is based on and claims the benefit of priority to Chinese Patent Application No. 202010692337.9, filed on July 17, 2020, and is hereby incorporated by reference in its entirety.
[0002] Technical Field This application relates to the field of chemical medicines, in particular to the use of 2,4,5-trisubstituted 1,2,4-triazolones in antiviral therapy. In vitro tests show that the compounds effectively inhibit various viral infections, in particular compound BAY2402234 has effective inhibitory effects on coronavirus, influenza virus, enterovirus, Zika virus, Bunyavirus, etc. [Background technology]
[0003] Background technology Viruses are non-cellular organisms that only have nucleic acid (DNA or RNA) and therefore must infect living cells and grow by replication. They infect organisms in various ways and replicate within susceptible host cells.
[0004] Viruses that infect humans cause various degrees of damage to the human body. For example, some diseases caused by viruses, such as HIV, Ebola virus, and rabies virus, are nearly fatal; other diseases caused by viruses, such as hepatitis caused by Hepatitis A, Hepatitis B, and other types of hepatitis 5 viruses, viral myocarditis caused by Coxsackievirus, influenza virus, etc., cause people to lose their workforce and even have lifelong disabilities. In addition, other viral diseases, such as dengue virus and Zika virus from the Flaviviridae family, Bunyaviridae from the Bunyaviridae family, and enterovirus from the Picornaviridae family, also pose serious threats to human health.
[0005] Among them, coronaviruses are enveloped, segmented, single-stranded positive-stranded RNA viruses that have a wide range of animal hosts. Zoonotic coronaviruses, such as SARS and MERS, can cause deaths in humans.
[0006] On February 11, 2020, the International Committee on Taxonomy Viruses (ICTV) announced a new coronavirus - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Later that same day, the World Health Organization (WHO) announced that the official name of the disease caused by this virus is COVID-19. Currently, COVID-19 is mainly treated with supportive care in outpatient clinics, and no specific antiviral drugs are available. There is an urgent and necessary need to develop drugs that effectively inhibit the above viruses, especially SARS-CoV-2.
[0007] Compounds of 2,4,5-trisubstituted 1,2,4-triazolones (formula (I) shown below) are novel antitumor drugs developed by Bayer AG. Antitumor activity is exerted by inhibiting tumor cell proliferation and inducing differentiation. The drugs provide potentially excellent clinical treatment in myeloid malignancies. Among those compounds, BAY2402234 has shown good antitumor activity both in vivo and in vitro and is currently undergoing phase I clinical trial studies in the indication of myeloid tumors. [ka] Summary of the Invention
[0008] Contents of the Invention In this study, the inventors found that BAY2402234 can inhibit various viruses and furthermore shows low cytotoxicity in some tests, which provides a new form and option for effectively preventing and / or treating diseases or symptoms caused by viruses.
[0009] In a first aspect, the disclosure provides the use of a compound of formula (I) or an N-oxide, tautomer, geometric isomer, solvate, hydrate, pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable salt of the tautomer or N-oxide thereof, in the manufacture of a medicament, wherein the medicament is for use in preventing and / or treating a disease associated with a virus, and the compound of formula (I) has the following structure: [ka] {In the formula, R 1 below: 3-pentyl, 2,2-dimethylpropyl, 4-heptyl, 4-fluorophenylcyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentylmethyl, cyclohexylmethyl, 1-cyclohexylethyl, 1-hydroxypropan-2-yl, 2-hydroxypropyl, 1-hydroxybutan-2-yl, 1-cyanobutan-2-yl, 1-phenylbutan-2-yl, 1-amino-2-propyl, 1-amino-2-butyl, 1-amino-1-oxobutan-2-yl, indan-2-yl, 5-6 membered heterocycloalkyl groups selected from tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl and piperidin-4-yl and optionally substituted once or twice by methyl groups; phenyl groups, optionally substituted one, two or three times, each substituent being independently selected from fluorine or chlorine atoms or groups selected from methyl, ethyl, propyl, isopropyl, difluoromethyl, trifluoromethyl, methoxy, -OC(=O)-1,1-dimethylethyl, hydroxy, -C(=O)OCH3, -C(=O)NH-cyclopropyl, amino, methylamino, aminomethyl, -S-CH3, -S(=O)2CH3, and -S(=O)(NH)CH3; and monocyclic heteroaryl groups selected from oxazol-2-yl, pyrazol-3-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, quinolin-5-yl, indazol-5-yl, and optionally substituted once or twice, each substituent being independently selected from methyl and methoxy; represents a group selected from
[0010] R 2 represents a hydrogen atom, or a fluorine or chlorine atom; R 3 represents a group selected from propyl, 2-methylpropyl, 3-pentyl, cyclopropylmethyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, difluoromethyl, trifluoromethyl, 1,1-difluoroethyl, prop-2-en-1-yl, 2-methyl-prop-1-en-1-yl, N,N-dimethylaminoethyl, and phenyl, R 4 represents a group selected from methyl, ethyl, propyl, isopropyl, 2-butyl, prop-2-en-1-yl, cyclopropylmethyl, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, and 2-hydroxyethyl,
[0011] R 5represents a chlorine atom or a group selected from methyl, ethyl, propyl, isopropyl, 2-butyl, isobutyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, trifluoromethyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxypropan-2-yl, 1-chloroethyl, 1-hydroxy-2,2,2-trifluoroethyl, 1-methoxyethyl, methoxy, isopropoxy, methylsulfanyl, aminomethyl, (methylamino)methyl, (dimethylamino)methyl, 1-aminoethyl, 2-aminoethyl, methylamino and ethyl(methyl)amino, -C(=O)OH, -C(=O)OCH3, -C(=O)NH2, -C(=O)NHCH3, -C(=O)NHcyclopropyl, -C(=O)N(CH3)2, and -S(=O)(=NH)CH3.
[0012] In some embodiments, the compound has the following formula II: [ka] It is a compound of the formula:
[0013] In some embodiments, the virus is an RNA virus. In some embodiments, the virus is a Coronaviridae virus, an Orthomyxoviridae virus, a Flaviviridae virus, a Bunyaviridae virus, a Picornaviridae virus, an Arenavirus, a Filoviridae virus, or a WEE virus.
[0014] In some embodiments, the virus is a Coronaviridae virus. In some embodiments, the Coronaviridae virus is selected from HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2.
[0015] In some embodiments, the virus is SARS-CoV-2. In some embodiments, the virus is an Orthomyxoviridae virus. In some embodiments, the virus is an influenza virus.
[0016] In some embodiments, the Orthomyxoviridae virus is an influenza virus. In some embodiments, the influenza virus is an influenza A virus (such as H1N1, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2, or H10N8), an influenza B virus, or an influenza C virus.
[0017] In some embodiments, the virus is a Flaviviridae virus. In some embodiments, the Flaviviridae virus is selected from Zika virus, Dengue virus, West Nile virus, Yellow fever virus, and HCV. In some embodiments, the virus is a Bunyaviridae virus. In some embodiments, the Bunyaviridae virus is a Bunyavirus or a Phlebovirus.
[0018] In some embodiments, the virus is a Picornaviridae virus. In some embodiments, the Picornaviridae virus is an enterovirus or a foot and mouth disease virus. In some embodiments, the virus is a Filoviridae virus. In some embodiments, the Filoviridae virus is selected from Ebola virus, Marburg virus, and Cueva virus.
[0019] In some embodiments, the agent is used to prevent and / or treat a disease caused by SARS-CoV, MERS-CoV, SARS-CoV-2, influenza virus, Zika virus, dengue virus, bunyavirus, or enterovirus. In some preferred embodiments, the agents are used to prevent and / or treat diseases caused by SARS-CoV, MERS-CoV, or SARS-CoV-2, such as SARS, MERS, or COVID-19.
[0020] BAY2402234 has excellent antiviral activity against coronaviruses, particularly SARS-CoV-2, and is therefore used to treat diseases caused by infection with viruses, such as simple infections such as fever, cough, sore throat, pneumonia, acute or severe respiratory infections, hypoxemic respiratory failure, acute respiratory distress syndrome, sepsis, and septic shock. Through creative research, the inventors have found that BAY2402234 inhibits the replication of SARS-CoV-2, and therefore has excellent therapeutic effects against diseases caused by SARS-CoV-2. Thus, in some particularly preferred embodiments, the medicament is used to prevent and / or treat diseases caused by SARS-CoV-2, such as COVID-19.
[0021] In some embodiments, the medicament is for human use. In some embodiments, the medicament is for veterinary use. In some embodiments, the medicament further comprises a pharma- ceutically acceptable carrier or adjuvant. In some embodiments, the compound is the only pharma- ceutical active ingredient.
[0022] In some embodiments, the compound is used in combination with other pharmacoactive ingredients. In some embodiments, the compound and other pharmacoactive ingredients are in the same preparation unit. In some embodiments, the compound and other pharmacoactive ingredients are in different preparation units. In some embodiments, the compound and other pharmacoactive ingredients are administered in parallel, separately or sequentially. In some embodiments, the other pharmacoactive ingredients are antiviral drugs such as amantadine, rimantadine, enfuvirtide, maraviroc, acyclovir, ganciclovir, valacyclovir, famciclovir, sodium phosphonate, lamivudine, zidovudine, entertabine, tenofovir, adefovir dipivoxil, efavirenz, nevirapine, saquinavir, oseltamivir, zanamivir, ribavirin, and interferon.
[0023] In some embodiments, the medicament is a solid formulation or a liquid formulation. In some embodiments, the medicament is a tablet, an injection, or a spray. In some embodiments, the medicament is a tablet or an injection.
[0024] In a second aspect, the disclosure also relates to the use of a compound as defined in the first aspect, or an N-oxide, tautomer, geometric isomer, solvate, hydrate, pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable salt of the tautomer or N-oxide thereof, in the manufacture of a medicament, wherein the medicament is for use in inhibiting viral replication or proliferation in a cell (e.g., a mammalian cell).
[0025] In some embodiments, the animal is a human, a dog, or a pig. In some embodiments, the medicament is for human or veterinary use. In some embodiments, the medicament further comprises a pharma- ceutically acceptable carrier or adjuvant.
[0026] In some embodiments, the compound is the only pharmacologic active ingredient or is used in combination with other pharmacologic active ingredients (eg, the medicament is a compound formulation). In some embodiments, the other pharmacologic active ingredient is an antiviral agent, such as one or more antiviral agents selected from amantadine, rimantadine, enfuvirtide, maraviroc, acyclovir, ganciclovir, valacyclovir, famciclovir, sodium phosphonate, lamivudine, zidovudine, entertabine, tenofovir, adefovir dipivoxil, efavirenz, nevirapine, saquinavir, oseltamivir, zanamivir, ribavirin, interferon, and the like.
[0027] In some embodiments, the agent is a solid or liquid formulation. In some embodiments, the medicament is a tablet, injection, spray, preferably a tablet or injection.
[0028] In a third aspect, the present disclosure also relates to the use of a compound as defined in the first aspect, or an N-oxide, tautomer, geometric isomer, solvate, hydrate, pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable salt of the tautomer or N-oxide thereof, in the manufacture of a virus inhibitor.
[0029] In some embodiments, the inhibitors are used to inhibit viral replication or proliferation in a cell (eg, a mammalian cell). In some embodiments, the host is a mammal. In some embodiments, the mammal is a human, dog, or pig.
[0030] In a fourth aspect, the disclosure relates to a method of preventing and / or treating a disease associated with a virus, comprising administering to a subject in need thereof an effective amount of a compound as defined in the first aspect, or an N-oxide, tautomer, geometric isomer, solvate, hydrate, pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable salt of the tautomer or N-oxide thereof.
[0031] In some embodiments, the subject is a mammal, such as a human. In some embodiments, the compound, or an N-oxide, tautomer, geometric isomer, solvate, hydrate, pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable salt of the tautomer or N-oxide thereof, is administered alone or in combination with other pharmaceutical components, e.g., administered concurrently, separately or sequentially.
[0032] In some embodiments, the other pharmacologic active ingredient is an antiviral agent, such as one or more antiviral agents selected from amantadine, rimantadine, enfuvirtide, maraviroc, acyclovir, ganciclovir, valacyclovir, famciclovir, sodium phosphonate, lamivudine, zidovudine, entertabine, tenofovir, adefovir dipivoxil, efavirenz, nevirapine, saquinavir, oseltamivir, zanamivir, ribavirin, interferon, and the like.
[0033] In a fifth aspect, the disclosure also relates to a method of inhibiting viral replication or proliferation in a cell (e.g., a mammalian cell), comprising administering to a subject in need thereof or contacting said cell with an effective amount of a compound as defined in the first aspect, or an N-oxide, tautomer, geometric isomer, solvate, hydrate, or a pharma- ceutically acceptable salt thereof, or a pharma-ceutically acceptable salt of the tautomer or N-oxide thereof.
[0034] In some embodiments, the subject is a mammal, such as a human. In some embodiments, the mammalian cell is derived from a human cell.
[0035] In some embodiments, the compound, or an N-oxide, tautomer, geometric isomer, solvate, hydrate, pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable salt of the tautomer or N-oxide thereof, is administered alone or in combination with other pharmaceutical components, e.g., administered concurrently, separately or sequentially.
[0036] In some embodiments, the other pharmacologic active ingredient is an antiviral agent, such as one or more selected from amantadine, rimantadine, enfuvirtide, maraviroc, acyclovir, ganciclovir, valacyclovir, famciclovir, sodium phosphonate, lamivudine, zidovudine, entertabine, tenofovir, adefovir dipivoxil, efavirenz, nevirapine, saquinavir, oseltamivir, zanamivir, ribavirin, and interferon.
[0037] The viruses and diseases in the second to fifth aspects are as defined in the first aspect. In some embodiments, the virus is a coronavirus, such as HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, or SARS-CoV-2, particularly SARS-CoV-2.
[0038] In some embodiments, the disease is a disease caused by SARS-CoV-2, such as an uncomplicated infection (e.g., fever, cough, and / or sore throat), pneumonia, acute or severe respiratory infection, hypoxemic respiratory failure, acute respiratory distress syndrome, sepsis, or septic shock, in particular COVID-19.
[0039] In this application, unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Also, the laboratory procedures of cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are all conventional methods and widely used in the corresponding fields. At the same time, for the purpose of better understanding the present invention, definitions and explanations for related terms are provided below.
[0040] As used herein, the term "pharmaceutical acceptable salt" includes inorganic or organic acid salts and inorganic or organic base salts such as sodium, potassium, calcium, lithium, meglumine, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, phosphate, hydrogen phosphate, acetate, propionate, butyrate, oxalate, trimethylacetate, adipate, alginate, lactate, citrate, tartrate, succinate, fumarate, picrate, aspartate, gluconate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate or pamoate salts.
[0041] As used herein, the term "geometric isomer" refers to stereoisomers resulting from different spatial arrangements in molecules having double bonds or cyclic structures due to the hindrance of the free rotation of an atom or group of atoms attached to the double bond or ring, such as cis / trans isomers.
[0042] The compound of formula (I) in the present disclosure may exist in the form of a solvate (preferably a hydrate), which contains a polar solvent, particularly water, methanol or ethanol, as a structural element of the lattice. The amount of polar solvent is stoichiometric or non-stoichiometric. It is understood that even though the solvates of the compound of formula (I) used to treat a disease or infection as defined herein may have different properties (including pharmacokinetic properties), when absorbed into a subject, the compound of formula (I) is obtained, such that the use of the compound of formula (I) encompasses the use of any solvate of the compound of formula (I).
[0043] Those skilled in the art should understand that not all nitrogen-containing heterocycles can form N-oxides because nitrogen requires an available lone pair electron to be oxidized to an oxide; however, those skilled in the art will recognize that nitrogen-containing heterocycles can form N-oxides. Those skilled in the art will also recognize that tertiary amines can form N-oxides. The synthetic methods used to prepare N-oxides of heterocycles and tertiary amines are well known to those skilled in the art. These include the use of peroxyacids such as peracetic acid, m-chloroperoxybenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethylbisethylene oxide to oxidize heterocycles and tertiary amines. These methods for preparing N-oxides have been widely described and reviewed in the literature, see for example TL Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750; AR Katritzky and AJ Boulton, Eds., Academic Press; as well as GWH Cheeseman and ESG Werstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, AR Katritzky and AJ Boulton, Eds., Academic Press.
[0044] Compounds of formula (I) may exist in mixtures of two or more structurally distinct forms that are in rapid equilibrium (commonly referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. It is to be understood that the scope of the present application encompasses all such isomers or mixtures thereof in any ratio (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%).
[0045] In this application, the term "therapeutically effective amount" or "prophylactically effective amount" refers to an amount sufficient to treat or prevent a disease in a patient, within the scope of reasonable medical judgment, but low enough to avoid serious side effects (at a reasonable benefit / risk ratio). The therapeutically effective amount of a compound may vary based on factors including the particular compound selected (e.g., taking into account the potency, efficacy and half-life of the compound), the selected route of administration, the disease being treated, the severity of the disease being treated, the age, size, weight and physical disease of the patient being treated, the medical history of the patient being treated, the duration of treatment, the nature of the combination therapy, the desired therapeutic effect, etc., but it can nevertheless be routinely determined by one of ordinary skill in the art.
[0046] In addition, it should be pointed out that the specific dose and route of administration of the compound of formula (I), or its geometric isomer, pharma- ceutically acceptable salt, solvate, or hydrate, will depend on many factors, including the patient's age, weight, sex, health status, nutritional status, drug potency, administration time, metabolic rate, disease severity, and the subjective judgment of the physician. A desirable dose is 0.001-1000 mg / kg body weight / day.
[0047] Description of the drawings The description of the drawings in this specification is provided for detailed description of the present invention and constitutes a part of this application. The exemplary embodiments and descriptions are intended to explain the present invention and should not be understood as any undue limitations on the present invention. [Brief description of the drawings]
[0048] [Figure 1]FIG. 1 shows the effect on viral RNA load in Vero E6 cells infected with SARS-CoV-2. Here, (a) shows that BAY2402234 inhibits viral RNA load in cells 24 hours after the cells were infected with SARS-CoV-2, and the inhibitory activity is dose-dependent; the left ordinate is the percentage inhibition calculated from the copy number of viral RNA load in the samples (corresponding to the red dots and the fitted curve therefrom), and the right ordinate is the percentage cytotoxicity calculated from the cell viability (corresponding to the blue dots and the fitted curve therefrom), and the abscissa is the drug concentration. (b) shows that BAY2402234 inhibits viral RNA levels in cells 48 hours after the cells are infected with SARS-CoV-2, and the inhibitory activity is dose-dependent; the left ordinate is the percentage inhibition calculated from the copy number of viral RNA levels in the samples (corresponding to the red dots and the fitted curve therefrom), and the right ordinate is the percentage cytotoxicity calculated from the cell viability (corresponding to the blue dots and the fitted curve therefrom), and the abscissa is the drug concentration. [Diagram 2] FIG. 2 shows the cytotoxicity of BAY2402234 and its in vitro anti-influenza virus activity. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0049] Specific Modes for Carrying Out the Invention The present invention is further illustrated clearly and completely in the following examples in conjunction with the drawings. Obviously, they are only a part of the examples, not the whole. At least one of the following examples is for aiding understanding, and should not be understood as any limitation on the present invention and its application and use. In addition, other embodiments made by those skilled in the art without creative work based on the present invention are all within the protection scope of the present invention. EXAMPLES
[0050] Example 1: Experimentation of BAY2402234 in reducing viral nucleic acid load in cells infected with SARS-CoV-2 (1) Drug treatment of virus-infected cells Vero E6 cells (purchased from ATCC, Catalog No. 1586) were placed in a 24-well plate and incubated for 24 hours, then virus infection was performed. Specifically, SARS-CoV-2 (2019-nCoV) virus (nCoV-2019BetaCoV / Wuhan / WIV04 / 2019 strain, provided by Wuhan Institute of Virology, Chinese Academy of Sciences) was diluted with 2% cell maintenance solution (formulation: FBS (purchased from Gibco, Catalog No.: 16000044) was added to MEM (purchased from Gibco, Product No.: 10370021) to a volume ratio of 2%, thereby obtaining a 2% cell maintenance solution) to the corresponding concentration, and then each well was inoculated with 100 TCID 50 Then, BAY2402234 (purchased from MCE, product number: HY-112645) was diluted with 2% cell maintenance solution to the corresponding concentration, and added to the corresponding wells so that the final drug concentrations were 100μM, 33μM, 11μM, 3.7μM, 1.23μM, 0.41μM, 0.14μM, respectively, and then the plate was placed in a 37℃, 5% CO2 incubator and continuously cultured for 48 hours, and the cell vehicle control group was only added with 2% cell maintenance solution without any test drug.
[0051] (2) RNA extraction The RNA extraction kit was purchased from Qiagen, product number: 74106. All consumables (spin columns, RNase-free 2 ml collection tubes, etc.) and reagents (RLT, RW1, RPE, RNase-free water, etc.) involved in the following RNA extraction steps were part of the kit. The following extraction steps were all recommended by the kit instruction manual.
[0052] 1) Remove 100 μL of the supernatant from the test plate and add it to a nuclease-free EP tube, then add 350 μL of Buffer RLT, mix with a transfer liquid gun to completely dissolve it, and then centrifuge and remove the supernatant; 2) Add the supernatant obtained in step 1) together with an equal volume of 70% ethanol and mix thoroughly; 3) Transfer the mixture obtained in step 2) above to an RNase-free spin column, centrifuge at 12000 rpm for 15 seconds, and discard the waste liquid;
[0053] 4) Add 700 μL of Buffer RW1 to the spin column, then centrifuge at 12000 rpm for 15 seconds to clean the spin column and discard the waste liquid; 5) Add 500 μL of Buffer RPE to the spin column, then centrifuge at 12000 rpm for 15 seconds to clean the spin column, and discard the waste liquid; 6) Add 500 μL of Buffer RPE to the spin column, then centrifuge at 12000 rpm for 2 minutes to clean the spin column, and discard the waste liquid;
[0054] 7) Place the spin column into a new 2 ml RNase-free collection tube and centrifuge at 12000 rpm for 1 minute to dry the spin column, then transfer the entire spin column to the 1.5 ml collection tube of step 8); 8) The spin column dried in step 7) was placed in a new 1.5 ml collection tube, 30 μl of RNase-free water was added, and the mixture was centrifuged at 12,000 rpm for 2 minutes to obtain the eluate containing the corresponding RNA, to which RNase inhibitor (purchased from NEB, product number: M0314L) was added, and the RNA concentration was measured by detection using Nano Drop (purchased from Thermo scientific, Nano Drop One).
[0055] (3) RNA reverse transcription In this experiment, a reverse transcription kit manufactured by TaKaRa Company (PrimeScript™ RT Reagent Kit with gDNA Eraser, Catalog No. RR047Q) was used for RNA reverse transcription. The steps were as follows:
[0056] 1) gDNA removal: RNA samples from each experimental group were collected, and 1 μg of each sample was taken and subjected to reverse transcription. First, 2 μl of 5× gDNA Eraser Buffer was added to each RNA sample from each experimental group, and the reaction system was supplemented with RNase-free water up to 10 μl, mixed thoroughly, and placed in a 42°C water bath for 2 minutes to remove gDNA present in the sample;
[0057] 2) Reverse transcription: To the sample obtained in 1), an appropriate amount of enzyme, primer mix, and reaction buffer were added, and RNase-free water was added to a volume of 20 μl. The mixture was reacted in a water bath at 37° C. for 15 minutes, and then placed in a water bath at 85° C. for 5 seconds, thereby obtaining cDNA by transcription.
[0058] (4) Real-time PCR Fluorescent quantitative PCR was used to detect the copy number per ml of the original virus solution. The reaction system was mixed using TB Green Premix (Takara, Cat#RR820A), and the amplification reaction and reading were performed using a StepOne Plus real-time PCR instrument (Brand: ABI). The copy number contained in 1 ml of the original virus solution was calculated. The steps were as follows:
[0059] 1) Establishment of the standard: Plasmid pMT-RBD (the plasmid was provided by Wuhan Institute of Virology, Chinese Academy of Sciences) was added to 5 × 10 8 Copies / µL, 5 x 10 7 Copies / µL, 5 x 10 6 Copies / µL, 5 x 10 5Copies / µL, 5 x 10 4 Copies / µL, 5 x 10 3 Copies / µL, 5 x 10 2 Diluted to copies / μL. 2 μL of standard or cDNA template was used in the qPCR reaction.
[0060] 2) The sequences of the primers used in the experiments were as follows (all shown in the 5′-3′ orientation): RBD-qF:CAATGGTTTAACAGGCACAGG RBD-qR:CTCAAGTGTCTGTGGATCACG
[0061] 3) The reaction procedure was as follows: Pre-denaturation: 95°C for 5 min; Cycle parameters: 95°C for 15 sec, 54°C for 15 sec, 72°C for 30 sec, total of 40 cycles. Inhibition rate (%) = (RNA copy number in drug-treated group) / (RNA copy number in infected group) × 100%
[0062] (5) Drug cytotoxicity test The detection of drug cytotoxicity was carried out using a CCK-8 kit (Beoytime). The specific steps were as follows:
[0063] 1) 1×10 4 Vero E6 (ATCC) cells were plated into 96-well plates and incubated at 37° C. for 8 hours. 2) Drugs were diluted with DMSO to the appropriate concentration of the mother solution, and then diluted with MEM medium (purchased from Gibco, catalog number 10370021) containing 2% FBS (purchased from Gibco, catalog number 16000044) to the same concentration as that of the drug treatment. The original medium in the 96-well plate was discarded, 100 μL of drug-containing MEM medium was added to the cells, and triplicate wells were prepared for each concentration. Vehicle controls (DMSO and medium were added to the cell wells, no drug was added) and blank controls (DMSO and medium were added to the wells, no cells) were set up. After adding the drugs, the cells were cultured at 37°C for 48 hours.
[0064] 3) 20 μL of CCK-8 solution (Beoytime) was added to the wells to be tested, mixed gently without creating bubbles, and incubated continuously for 2 hours at 37°C. OD 450 was read by a microplate reader (purchased from Molecular Devices, model: SpectraMax M5), and the cell viability was calculated: Cell activity (%) = (A (薬物処置群) -A (ブランク対照) ) / (A (ビヒクル対照) -A (ブランク対照) )×100% where A was the readout of the microplate reader.
[0065] (6) Experimental results The results of the viral growth inhibition experiment showed that the test compounds at concentrations of 10 μM, 3.3 μM, 1.1 μM, 0.3 μM, 0.1 μM, and 0.03 μM could effectively inhibit the replication of the SARS-CoV-2 viral genome in the infected supernatant (Figure 1). The results of the cytotoxicity test showed that treatment with the test compound (BAY2402234) did not alter cell viability below 10 μM, i.e., the test compound had no toxic effect on the cells at all tested concentrations (FIG. 1).
[0066] (7) Conclusion Compound BAY2402234 significantly inhibited SARS-CoV-2 isolate nCoV-2019BetaCoV / Wuhan / WIV04 / 2019, and the EC 50 were 0.0070 μM and 0.0027 μM at 24 and 48 hours after infection, respectively, and CC 50 is 198.8 μM and the corresponding treatment indices SI are 28400 and 73629.63, respectively.
[0067] Example 2: In vitro evaluation of anti-influenza virus activity and safety of BAY2402234 (1) Evaluation of anti-influenza virus activity of drugs 1) MDCK cells (purchased from ATCC, catalog number: CCL-34) were cultured at 1.5 × 10 4 The cells were inoculated into a 96-well plate at a concentration of 100 cells / well in DMEM (purchased from Gibco, catalog number: 11995065) containing 10% FBS (purchased from Gibco, catalog number: 16000044) and cultured at 37°C in a CO2 incubator for 24 hours.
[0068] 2) Before the experiment, the cells were washed three times with PBS (purchased from Gibco, catalog number: 10010049) and 100 μL of D / F-12 medium (purchased from Gibco, catalog number: 11330032) containing 2 μg / mL of TPCK (purchased from Sigma, catalog number: T1426) was added. Then, 50 mM BAY2402234 (purchased from MCE, catalog number: HY-112645) mother solution was serially diluted with the above D / F-12 medium to 0.444 μM, 0.148 μM, 0.049 μM, 0.016 μM, 0.005 μM, 1.829 nM, 0.609 nM, and 0.203 nM, and 50 μL of each was added to the cell culture plate. Finally, influenza viruses A / PR / 8 (stored at the Academy of Military Medical Sciences), A / California / 07 / 2009 (stored at the Academy of Military Medical Sciences), A / Hongkong / 08 / 1968 (purchased from ATCC, catalog number: VR1679), A / Zhenxing1109 / 2010 (stored at the Academy of Military Medical Sciences), and B / Lee / 40 (purchased from ATCC, catalog number: VR1535) were diluted to the corresponding concentrations in D / F-12 medium containing 2 μg / mL TPCK, and 50 μL of the dilutions were added to each well at 100 TCID 50 The final concentration of the drug was 0.25 times that of the drug before treatment, i.e., the drug with an initial concentration of 0.111 μM was diluted in a 3-fold serial manner to reach final concentrations of 0.111 μM, 0.037 μM, 0.012 μM, 0.004 μM, 0.0014 μM, 0.457 nM, 0.152 nM, and 0.051 nM. Negative controls (wells with only DMSO and culture medium, no drug) and positive controls (wells with DMSO, culture medium, and virus, no drug) were set up. The cells were cultured at 37° C. for 72 hours.
[0069] 3) The buffer and substrate of CellTiter-Glo® Luminescent Cell Viability Assay Kit (purchased from Promega, catalog number: G7573) were mixed in the dark as a working solution. The working solution and PBS were mixed in a ratio of 4:6. The liquid in the cell culture plate was discarded, and then 100 μl of the test reagent was added to each well, and the 96-well plate was shaken with an Orbital vibrator for 7 minutes to cause cell lysis. After stabilizing the signal for 5 minutes in the dark, the chemiluminescence was measured by an enzyme labeling device (purchased from Molecular Devices, SpectraMax M5), the plate reading program was the CellTiter-Glo preset program, and the cell viability was calculated: Cell viability (%)=(A (薬物処置群) -A (陽性対照群) ) / (A (陰性対照群) -A (陽性対照群) )×100% where A was the readout from the enzyme labeling instrument.
[0070] (2) Drug cytotoxicity test 1) MDCK cells (purchased from ATCC, catalog number: CCL-34) were cultured at 1.5 × 10 4 The cells were inoculated into a 96-well plate at a concentration of 100 cells / well in DMEM (purchased from Gibco, catalog number: 11995065) containing 10% FBS (purchased from Gibco, catalog number: 16000044) and cultured at 37°C in a CO2 incubator for 24 hours.
[0071] 2) Before the experiment, the cells were washed three times with PBS (purchased from Gibco, catalog number: 10010049) and 150 μL of D / F-12 medium (purchased from Gibco, catalog number: 11330032) containing 2 μg / mL of TPCK (purchased from Sigma, catalog number: T1426) was added. Then, 50 mM BAY2402234 (purchased from MCE, catalog number: HY-112645) mother solution was serially diluted with the above D / F-12 medium to 4 μM, 1.333 μM, 0.444 μM, 0.148 μM, 0.049 μM, 0.016 μM, 0.005 μM, 1.829 nM, 0.609 nM, and 0.203 nM, and 50 μL of each was added to the cell culture plate. The final concentration of the drug was 0.25 times that of the drug before treatment, i.e., the drug with 1 μM as the initial concentration was diluted in a 3-fold serial manner to reach the final concentrations of 1 μM, 0.333 μM, 0.111 μM, 0.037 μM, 0.012 μM, 0.004 μM, 0.0014 μM, 0.457 nM, 0.152 nM, and 0.051 nM. A negative control group (wells with only DMSO and culture medium, no drug) was set up. The cells were cultured at 37° C. for 72 hours.
[0072] 3) The buffer and substrate of CellTiter-Glo® Luminescent Cell Viability Assay Kit (purchased from Promega, catalog number: G7573) were mixed in the dark as a working solution. The working solution and PBS were mixed in a ratio of 4:6. The liquid in the cell culture plate was discarded, and then 100 μl of the test reagent was added to each well, and the 96-well plate was shaken with an Orbital vibrator for 7 minutes to cause cell lysis. After stabilizing the signal for 5 minutes in the dark, the chemiluminescence was measured by an enzyme labeling device (purchased from Molecular Devices, SpectraMax M5), the plate reading program was the CellTiter-Glo preset program, and the cytotoxicity was calculated: Cytotoxicity (%)=(A (陰性対照群) -A (薬物処置群) ) / A (陰性対照群) )×100% where A was the readout from the enzyme labeling instrument.
[0073] (3) Test results In vitro antiviral studies have demonstrated the EC of test compound BAY2402234 for inhibition of influenza viruses A / PR / 8, A / California / 07 / 2009, A / Hongkong / 08 / 1968, A / Zhenxing1109 / 2010, and B / Lee / 40. 50 were 0.01±0.0003 μM, 0.03±0.009 μM, 0.007±0.003 μM, 0.04±0.01 μM, and 0.03±0.02 μM, respectively (as shown in Table 1); the cytotoxicity test showed that the CC 50 is 0.27±0.09 μM (shown in Table 1), and the corresponding treatment indices are 27, 9, 38.57, 6.75, and 9, respectively.
[0074] (4) Conclusion The compound BAY2402234 has a relatively broad antibacterial spectrum inhibitory effect against influenza viruses (H1N1, H1N1-Oseltamivir-resistant strains, H3N2, type B).
[0075] [Table 1]
[0076] Example 3: In vitro evaluation of anti-Zika virus activity and safety of BAY2402234 (1) Evaluation of anti-Zika virus activity of drugs 1) BHK cells (stored at the Academy of Military Medical Sciences) or Vero cells (stored at the Academy of Military Medical Sciences) were used at a concentration of 5 × 10 for BHK cells. 3 Cells / well and 1 x 10 for Vero cells 4The cells were inoculated into a 96-well plate at a concentration of 100 cells / well in DMEM (purchased from Gibco, catalog number: 11995065) containing 10% FBS (purchased from Gibco, catalog number: 16000044) and cultured at 37°C in a CO2 incubator for 24 hours.
[0077] 2) Discard the culture medium in the 96-well plate, and add 100 μL of DMEM medium (purchased from Gibco, catalog number: 11995065) containing 2% FBS (purchased from Gibco, catalog number: 16000044). Next, 50 mM BAY2402234 (purchased from MCE, catalog number: HY-112645) mother solution was diluted in a serial manner with the above DMEM medium to 800 nM, 266.67 nM, 88.89 nM, 29.63 nM, 9.88 nM, 3.29 nM, 1.10 nM, and 0.37 nM, and 50 μL of each was added to the cell culture plate. Finally, 50 μL of Zika virus strain SZ-SMGC-01 (stored at Academy of Military Medical Sciences) diluted in DMEM medium containing 2% FBS was added to each well at 100 TCID 50 The final concentration of the drug was 0.25 times that of the drug before treatment, i.e., the drug with 200nM as the initial concentration was diluted in a 3-fold serial manner to reach the final concentrations of 200nM, 66.67nM, 22.22nM, 7.41nM, 2.47nM, 0.82nM, 0.27nM, and 0.09nM. Negative controls (wells with only DMSO and culture medium, no drug) and positive controls (wells with DMSO, culture medium, and virus, no drug) were set up. BHK cells were cultured at 37°C for 9 days, and Vero cells were cultured for 7 days.
[0078] 3) The buffer and substrate of CellTiter-Glo® Luminescent Cell Viability Assay Kit (purchased from Promega, catalog number: G7573) were mixed in the dark as a working solution. The working solution and PBS (purchased from Gibco, catalog number: 10010049) were mixed in a ratio of 4:6. The liquid in the cell culture plate was discarded, and then 100 μl of the test reagent was added to each well, and the 96-well plate was shaken with an Orbital vibrator for 5 minutes to cause cell lysis. After stabilizing the signal for 2 minutes in the dark, the chemiluminescence was measured by an enzyme labeling device (purchased from Molecular Devices, SpectraMax M5), the plate reading program was the CellTiter-Glo preset program, and the cell viability was calculated: Cell viability (%)=(A (薬物処置群) -A (陽性対照群) ) / (A (陰性対照群) -A (陽性対照群) )×100% where A was the readout from the enzyme labeling instrument.
[0079] (2) Drug cytotoxicity test 1) BHK cells (stored at the Academy of Military Medical Sciences) or Vero cells (stored at the Academy of Military Medical Sciences) were used at a concentration of 5 × 10 3 Cells / well and 1 x 10 for Vero cells 4 The cells were inoculated into a 96-well plate at a concentration of 100 cells / well in DMEM (purchased from Gibco, catalog number: 11995065) containing 10% FBS (purchased from Gibco, catalog number: 16000044) and cultured at 37°C in a CO2 incubator for 24 hours.
[0080] 2) Discard the culture medium in the 96-well plate, and add 150 μL of DMEM medium (purchased from Gibco, catalog number: 11995065) containing 2% FBS (purchased from Gibco, catalog number: 16000044). Next, 50 mM BAY2402234 (purchased from MCE, catalog number: HY-112645) mother solution was serially diluted with the above DMEM medium to 800 nM, 266.67 nM, 88.89 nM, 29.63 nM, 9.88 nM, 3.29 nM, 1.10 nM, and 0.37 nM, and 50 μL of each was added to the cell culture plate. The final concentration of the drug was 0.25 times that of the drug before treatment, i.e., the drug with 200nM as the initial concentration was diluted in a 3-fold serial manner to reach the final concentrations of 200nM, 66.67nM, 22.22nM, 7.41nM, 2.47nM, 0.82nM, 0.27nM, and 0.09nM. Negative controls (wells with only DMSO and culture medium, no drug) were set up. BHK cells were cultured at 37°C for 9 days, and Vero cells were cultured for 7 days.
[0081] 3) The buffer and substrate of CellTiter-Glo® Luminescent Cell Viability Assay Kit (purchased from Promega, catalog number: G7573) were mixed in the dark as a working solution. The working solution and PBS (purchased from Gibco, catalog number: 10010049) were mixed in a ratio of 4:6. The liquid in the cell culture plate was discarded, and then 100 μl of the test reagent was added to each well, and the 96-well plate was shaken with an Orbital vibrator for 5 minutes to cause cell lysis. After stabilizing the signal for 2 minutes in the dark, the chemiluminescence was measured by an enzyme labeling device (purchased from Molecular Devices, SpectraMax M5), the plate reading program was the CellTiter-Glo preset program, and the cytotoxicity was calculated: Cytotoxicity (%)=(A (陰性対照群) -A (薬物処置群) ) / A (陰性対照群) )×100% where A was the readout from the enzyme labeling instrument.
[0082] (3) Test results Preliminary results showed that the test compound BAY2402234 had an inhibitory effect against Zika virus.
[0083] Example 4: In vitro evaluation of anti-bunyavirus activity and safety of BAY2402234 (1) Evaluation of anti-bunyavirus activity of drugs 1) Huh7 cells (stored at the Academy of Military Medical Sciences) were cultured at 5 × 10 3 The cells were inoculated into a 96-well plate at a concentration of 100 cells / well in DMEM (purchased from Gibco, catalog number: 11995065) containing 10% FBS (purchased from Gibco, catalog number: 16000044) and cultured at 37°C in a CO2 incubator for 24 hours.
[0084] 2) Discard the culture medium in the 96-well plate, and add 100 μL of DMEM medium (purchased from Gibco, catalog number: 11995065) containing 2% FBS (purchased from Gibco, catalog number: 16000044). Next, 50 mM BAY2402234 (purchased from MCE, catalog number: HY-112645) mother solution was diluted in a serial manner with the above DMEM medium to 800 nM, 266.67 nM, 88.89 nM, 29.63 nM, 9.88 nM, 3.29 nM, 1.10 nM, and 0.37 nM, and 50 μL of each was added to the cell culture plate. Finally, 50 μL of Bunyavirus strain (isolated in the laboratory: from patient serum of Beijing Ditan Hospital Capital Medical University) diluted with DMEM medium containing 2% FBS was added to each well at 100 TCID 50The final concentration of the drug was 0.25 times that of the drug before treatment, i.e., the drug with 200nM as the initial concentration was diluted in a 3-fold serial manner to reach the final concentrations of 200nM, 66.67nM, 22.22nM, 7.41nM, 2.47nM, 0.82nM, 0.27nM, and 0.09nM. Negative controls (wells with only DMSO and culture medium, no drug) and positive controls (wells with DMSO, culture medium, and virus, no drug) were set up. The cells were cultured at 37°C for 6 days.
[0085] 3) The buffer and substrate of CellTiter-Glo® Luminescent Cell Viability Assay Kit (purchased from Promega, catalog number: G7573) were mixed in the dark as a working solution. The working solution and PBS (purchased from Gibco, catalog number: 10010049) were mixed in a ratio of 4:6. The liquid in the cell culture plate was discarded, and then 100 μl of the test reagent was added to each well, and the 96-well plate was shaken with an Orbital vibrator for 5 minutes to cause cell lysis. After stabilizing the signal for 2 minutes in the dark, the chemiluminescence was measured by an enzyme labeling device (purchased from Molecular Devices, SpectraMax M5), the plate reading program was the CellTiter-Glo preset program, and the cell viability was calculated: Cell viability (%)=(A (薬物処置群) -A (陽性対照群) ) / (A (陰性対照群) -A (陽性対照群) )×100% where A was the readout from the enzyme labeling instrument.
[0086] (2) Drug cytotoxicity test 1) Huh7 cells (stored at the Academy of Military Medical Sciences) were cultured at 5 × 10 3The cells were inoculated into a 96-well plate at a concentration of 100 cells / well in DMEM (purchased from Gibco, catalog number: 11995065) containing 10% FBS (purchased from Gibco, catalog number: 16000044) and cultured at 37°C in a CO2 incubator for 24 hours.
[0087] 2) Discard the culture medium in the 96-well plate, and add 150 μL of DMEM medium (purchased from Gibco, catalog number: 11995065) containing 2% FBS (purchased from Gibco, catalog number: 16000044). Next, 50 mM BAY2402234 (purchased from MCE, catalog number: HY-112645) mother solution was serially diluted with the above DMEM medium to 800 nM, 266.67 nM, 88.89 nM, 29.63 nM, 9.88 nM, 3.29 nM, 1.10 nM, and 0.37 nM, and 50 μL of each was added to the cell culture plate. The final concentration of the drug was 0.25 times that of the drug before treatment, i.e., the drug with 200nM as the initial concentration was diluted in a 3-fold serial manner to reach the final concentrations of 200nM, 66.67nM, 22.22nM, 7.41nM, 2.47nM, 0.82nM, 0.27nM, and 0.09nM. Negative controls (wells with only DMSO and culture medium, no drug) were set up. The cells were cultured at 37°C for 6 days.
[0088] 3) The buffer and substrate of CellTiter-Glo® Luminescent Cell Viability Assay Kit (purchased from Promega, catalog number: G7573) were mixed in the dark as a working solution. The working solution and PBS (purchased from Gibco, catalog number: 10010049) were mixed in a ratio of 4:6. The liquid in the cell culture plate was discarded, and then 100 μl of the test reagent was added to each well, and the 96-well plate was shaken with an Orbital vibrator for 5 minutes to cause cell lysis. After stabilizing the signal for 2 minutes in the dark, the chemiluminescence was measured by an enzyme labeling device (purchased from Molecular Devices, SpectraMax M5), the plate reading program was the CellTiter-Glo preset program, and the cytotoxicity was calculated: Cytotoxicity (%)=(A (陰性対照群) -A (薬物処置群) ) / A (陰性対照群) )×100% where A was the readout from the enzyme labeling instrument.
[0089] (3) Test results Preliminary results showed that the test compound BAY2402234 had an inhibitory effect against Bunyaviruses.
[0090] Example 5: In vitro evaluation of anti-enteroviral activity and safety of BAY2402234 (1) Evaluation of anti-enterovirus activity of drugs 1) Vero cells (purchased from ATCC, catalog number: CCL-81) were cultured at 1 × 10 4 The cells were seeded into a 96-well plate at a concentration of 100 cells / well in DMEM (purchased from Gibco, catalog number: 11995065) containing 2% FBS (purchased from Gibco, catalog number: 16000044) and cultured at 37°C in a CO2 incubator for 24 hours.
[0091] 2) Before the experiment, the cells were washed three times with PBS (purchased from Gibco, catalog number: 10010049), and 100 μL of DMEM medium (purchased from Gibco, catalog number: 11995065) containing 2% FBS (purchased from Gibco, catalog number: 16000044) was added. Then, 50 mM BAY2402234 (purchased from MCE, catalog number: HY-112645) mother solution was serially diluted with the above DMEM medium to 40 μM, 13.33 μM, 4.44 μM, 1.48 μM, 0.49 μM, 0.16 μM, 0.05 μM, 18.29 nM, 6.09 nM, and 2.03 nM, and 50 μL of each was added to the cell culture plate. Finally, 50 μL of enterovirus strain CB3 (stored at the Academy of Military Medical Sciences) diluted in DMEM medium containing 2% FBS was added to each well at a concentration of 100 TCID 50 The final concentration of the drug was 0.25 times that of the drug before treatment, i.e., the drug with 10 μM as the initial concentration was diluted in a 3-fold serial manner to reach the final concentrations of 10 μM, 3.33 μM, 1.11 μM, 0.37 μM, 0.12 μM, 0.04 μM, 13.72 nM, 4.57 nM, 1.52 nM, and 0.51 nM. Negative controls (wells with only DMSO and culture medium, no drug) and positive controls (wells with DMSO, culture medium, and virus, no drug) were set up. The cells were cultured at 37° C. for 5 days.
[0092] 3) The buffer and substrate of CellTiter-Glo® Luminescent Cell Viability Assay Kit (purchased from Promega, catalog number: G7573) were mixed in the dark as a working solution. The working solution and PBS were mixed in a ratio of 4:6. The liquid in the cell culture plate was discarded, and then 100 μl of the test reagent was added to each well, and the 96-well plate was shaken with an Orbital vibrator for 5 minutes to cause cell lysis. After stabilizing the signal for 3 minutes in the dark, the chemiluminescence was measured by an enzyme labeling device (purchased from Molecular Devices, SpectraMax M5), the plate reading program was the CellTiter-Glo preset program, and the cell viability was calculated: Cell viability (%)=(A (薬物処置群) -A (陽性対照群) ) / (A (陰性対照群) -A (陽性対照群) )×100% where A was the readout from the enzyme labeling instrument.
[0093] (2) Drug cytotoxicity test 1) Vero cells (purchased from ATCC, catalog number: CCL-81) were cultured at 1 × 10 4 The cells were inoculated into a 96-well plate at a concentration of 100 cells / well in DMEM (purchased from Gibco, catalog number: 11995065) containing 10% FBS (purchased from Gibco, catalog number: 16000044) and cultured at 37°C in a CO2 incubator for 24 hours.
[0094] 2) Before the experiment, the cells were washed three times with PBS (purchased from Gibco, catalog number: 10010049), and 150 μL of DMEM medium (purchased from Gibco, catalog number: 11995065) containing 2% FBS (purchased from Gibco, catalog number: 16000044) was added. Then, 50 mM BAY2402234 (purchased from MCE, catalog number: HY-112645) mother solution was serially diluted with the above DMEM medium to 40 μM, 13.33 μM, 4.44 μM, 1.48 μM, 0.49 μM, 0.16 μM, 0.05 μM, 18.29 nM, 6.09 nM, and 2.03 nM, and 50 μL of each was added to the cell culture plate. The final concentration of the drug is 0.25 times that of the drug before treatment, i.e., the drug with 10 μM as the initial concentration is diluted in a 3-fold serial manner to reach the final concentrations of 10 μM, 3.33 μM, 1.11 μM, 0.37 μM, 0.12 μM, 0.04 μM, 13.72 nM, 4.57 nM, 1.52 nM, and 0.51 nM. Negative controls (wells with only DMSO and culture medium, no drug) were set up. Cells were cultured at 37°C for 5 days.
[0095] 3) The buffer and substrate of CellTiter-Glo® Luminescent Cell Viability Assay Kit (purchased from Promega, catalog number: G7573) were mixed in the dark as a working solution. The working solution and PBS (purchased from Gibco, catalog number: 10010049) were mixed in a ratio of 4:6. The liquid in the cell culture plate was discarded, and then 100 μl of the test reagent was added to each well, and the 96-well plate was shaken with an Orbital vibrator for 5 minutes to cause cell lysis. After stabilizing the signal for 3 minutes in the dark, the chemiluminescence was measured by an enzyme labeling device (purchased from Molecular Devices, SpectraMax M5), the plate reading program was the CellTiter-Glo preset program, and the cytotoxicity was calculated: Cytotoxicity (%)=(A (陰性対照群) -A (薬物処置群) ) / A (陰性対照群) )×100% where A was the readout from the enzyme labeling instrument.
[0096] (3) Test results Preliminary results showed that the test compound BAY2402234 had an inhibitory effect against enteroviruses.
[0097] [Table 2]
[0098] In addition to those described herein, various modifications of the present invention will become apparent to those skilled in the art from the above description. Such modifications also fall within the scope of the appended claims. Each reference cited in this application (including all patents, patent applications, journal articles, books, and other publications) is hereby incorporated by reference in its entirety.
Claims
1. 2. Use of a compound of formula (I) or an N-oxide, tautomer, geometric isomer, solvate, hydrate, pharma- ceutically acceptable salt thereof, or a pharma-ceutically acceptable salt of the tautomer or N-oxide thereof, in the manufacture of a medicament, wherein the medicament is for use in the prophylaxis and / or treatment of a disease associated with a virus, and the compound of formula (I) is 【Chemistry 1】 {During the ceremony, R 1 Below: 3-pentyl, 2,2-dimethylpropyl, 4-heptyl, 4-fluorophenylcyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentylmethyl, cyclohexylmethyl, 1-cyclohexylethyl, 1-hydroxypropan-2-yl, 2-hydroxypropyl, 1-hydroxybutan-2-yl, 1-cyanobutan-2-yl, 1-phenylbutan-2-yl, 1-amino-2-propyl, 1-amino-2-butyl, 1-amino-1-oxobutan-2-yl, indan-2-yl, 5-6 membered heterocycloalkyl groups selected from tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl and piperidin-4-yl, and optionally substituted once or twice by methyl groups; Optionally substituted one, two or three times, each substituent being a fluorine or chlorine atom or methyl, ethyl, propyl, isopropyl, difluoromethyl, trifluoromethyl, methoxy, -O-C(=O)-1,1-dimethylethyl, hydroxy, -C(=O)OCH 3 , -C(=O)NH-cyclopropyl, amino, methylamino, aminomethyl, -S-CH 3 , -S(=O) 2 CH 3 and -S(=O)(NH)CH 3 a phenyl group independently selected from the groups monocyclic heteroaryl groups selected from oxazol-2-yl, pyrazol-3-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, quinolin-5-yl, indazol-5-yl, and optionally substituted once or twice, each substituent being independently selected from methyl and methoxy; represents a group selected from R 2 represents a hydrogen atom, or a fluorine or chlorine atom; R 3 represents a group selected from propyl, 2-methylpropyl, 3-pentyl, cyclopropylmethyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, difluoromethyl, trifluoromethyl, 1,1-difluoroethyl, prop-2-en-1-yl, 2-methyl-prop-1-en-1-yl, N,N-dimethylaminoethyl, and phenyl, R 4 represents a group selected from methyl, ethyl, propyl, isopropyl, 2-butyl, prop-2-en-1-yl, cyclopropylmethyl, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, and 2-hydroxyethyl, R 5 is a chlorine atom, or methyl, ethyl, propyl, isopropyl, 2-butyl, isobutyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, trifluoromethyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxypropan-2-yl, 1-chloroethyl, 1-hydroxy-2,2,2-trifluoroethyl, 1-methoxyethyl, methoxy, isopropoxy, methylsulfanyl, aminomethyl, (methylamino)methyl, (dimethylamino)methyl, 1-aminoethyl, 2-aminoethyl, methylamino and ethyl(methyl)amino, -C(=O)OH, -C(=O)OCH 3 , -C(=O)NH 2 , -C(=O)NHCH 3 , -C(=O)NHcyclopropyl, -C(=O)N(CH 3 ) 2 and -S(=O)(=NH)CH 3 represents a group selected from the group consisting of
2. The compound has the following formula II: 【Chemistry 2】 The use according to claim 1, wherein the compound is
3. 13. Use of a compound according to claim 1 or 2, or an N-oxide, tautomer, geometric isomer, solvate, hydrate, pharma- ceutically acceptable salt thereof, in the manufacture of a medicament, wherein the medicament is used for inhibiting viral replication or proliferation in mammalian cells.
4. The use according to any one of claims 1 to 3, wherein the virus is an RNA virus.
5. The use according to any one of claims 1 to 4, wherein the virus is a Coronaviridae virus, an Orthomyxoviridae virus, a Flaviviridae virus, a Bunyaviridae virus, a Picornaviridae virus, an Arenavirus, a Filoviridae virus, or a WEE virus.
6. The coronavirus family virus is selected from HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2, and / or the Orthomyxoviridae virus is selected from influenza A virus, influenza B virus, and influenza C virus; and / or the Flaviviridae virus is selected from Zika virus, Dengue virus, West Nile virus, Yellow fever virus, and HCV; and / or the Bunyaviridae virus is a Bunyavirus or a Phlebovirus, and / or the Picornaviridae virus is an enterovirus or a foot and mouth disease virus, and / or 6. The use according to claim 5, wherein the Filoviridae virus is selected from Ebola virus, Marburg virus, and Cueva virus.
7. The use according to any one of claims 1 to 6, wherein the medicament is used for the prevention and / or treatment of a disease caused by SARS-CoV, MERS-CoV, SARS-CoV-2, influenza virus, Zika virus, dengue virus, bunyavirus, or enterovirus.
8. The use according to claim 7, wherein the disease caused by SARS-CoV-2 is uncomplicated infection, pneumonia, acute or severe respiratory infection, hypoxemic respiratory failure, acute respiratory distress syndrome, sepsis, or septic shock.
9. The use described in claim 8, wherein the uncomplicated infection is fever, cough, and / or sore throat.
10. The use according to any one of claims 1 to 9, wherein the medicament is used for the prevention and / or treatment of COVID-19.
11. The use according to any one of claims 1 to 10, wherein the medicament is for human or veterinary use.
12. The use according to any one of claims 1 to 11, wherein the medicament further comprises a pharma- ceutically acceptable carrier or excipient.
13. The use according to any one of claims 1 to 12, wherein the compound is the only pharmacologic active ingredient or is used in combination with another pharmacologic active ingredient, the other pharmacologic active ingredient being selected from antiviral drugs.
14. The use of claim 13, wherein the antiviral drug is one or more antiviral drugs selected from amantadine, rimantadine, enfuvirtide, maraviroc, acyclovir, ganciclovir, valacyclovir, famciclovir, sodium phosphonate, lamivudine, zidovudine, entertabine, tenofovir, adefovir dipivoxil, efavirenz, nevirapine, saquinavir, oseltamivir, zanamivir, ribavirin, and interferon.
15. The use according to any one of claims 1 to 14, wherein the medicament is a solid formulation or a liquid formulation.
16. The use of claim 15, wherein the medicament is a tablet, injection, or spray.
Citation Information
Patent Citations
5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
EP3553052A1
2,4,5-Trisubstituted 1,2,4-Triazolones as Potential Inhibitors of DHODH
JP2019533694A
4,5-fused 1,2,4-triazolone
JP2019535689A
2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
WO2018077923A1
Method for the preparation of a 2,4,5-trisubstituted 1,2,4-triazolone
WO2019197239A1
